PD-1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report. (PubMed, Clin Case Rep) - Sep 28, 2026 - "In a patient with advanced ovarian cancer showing limited response to paclitaxel-carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease-free status during olaparib-bevacizumab maintenance. This case provides a rationale for further investigation of PD-1 blockade as neoadjuvant therapy in carefully selected patients with suboptimal response to platinum-taxane chemotherapy."
Journal • Oncology • Ovarian Cancer • Solid Tumor
|